Johnson & Johnson $JNJ Position Trimmed by Railway Pension Investments Ltd

Key Points

• Railway Pension Investments Ltd cut its Johnson & Johnson stake by 31.2% in the fourth quarter, selling 327,800 shares and leaving it with 723,436 shares valued at about $149.7 million.
• Johnson & Johnson’s latest business updates were largely positive, with encouraging data for RYBREVANT + LAZCLUZE, TECVAYLI, and a FDA label expansion for TREMFYA in psoriatic arthritis.
• The company continues to show solid financials and shareholder returns: it beat quarterly earnings expectations, raised its dividend to $1.34 per share, and now has a consensus analyst rating of Moderate Buy.

Railway Pension Investments Ltd lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 31.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 723,436 shares of the company's stock after selling 327,800 shares during the quarter. Johnson & Johnson makes up 1.8% of Railway Pension Investments Ltd's investment portfolio, making the stock its 27th largest holding. Railway Pension Investments Ltd's holdings in Johnson & Johnson were worth $149,715,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. AustralianSuper Pty Ltd lifted its holdings in Johnson & Johnson by 632.0% in the 3rd quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company's stock worth $16,536,000 after purchasing an additional 77,000 shares during the last quarter. J.W. Cole Advisors Inc. lifted its holdings in shares of Johnson & Johnson by 2.2% during the third quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company's stock worth $24,278,000 after buying an additional 2,769 shares during the last quarter. Guinness Asset Management LTD lifted its holdings in shares of Johnson & Johnson by 0.4% during the third quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company's stock worth $251,216,000 after buying an additional 5,994 shares during the last quarter. Greenberg Financial Group bought a new position in Johnson & Johnson in the fourth quarter worth $954,000. Finally, National Pension Service lifted its position in Johnson & Johnson by 3.2% in the third quarter. National Pension Service now owns 4,926,569 shares of the company's stock worth $913,484,000 after purchasing an additional 151,707 shares during the period. Institutional investors own 69.55% of the company's stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported updated Phase 1/1b data showing RYBREVANT plus LAZCLUZE delivered prolonged clinical benefit in atypical EGFR-mutated non-small cell lung cancer, with median overall survival nearing 3.5 years. This strengthens the case for the company’s lung cancer pipeline. Article Title
• Positive Sentiment: New Phase 3 MajesTEC-9 data showed TECVAYLI improved progression-free and overall survival versus standard of care in relapsed multiple myeloma, reinforcing Johnson & Johnson’s momentum in blood-cancer treatments and expanding confidence in the drug’s earlier-line use. Article Title
• Positive Sentiment: The FDA approved a label expansion for TREMFYA in psoriatic arthritis, adding evidence that it can help stop structural joint damage. That makes TREMFYA more differentiated in a large immunology market and may support future sales growth. Article Title
• Neutral Sentiment: Several analyst and market commentary pieces noted that JNJ has outperformed the Dow and that Wall Street sentiment remains moderately optimistic, but these were mostly retrospective and did not add new fundamental catalysts. Article Title
• Neutral Sentiment: Johnson & Johnson also announced it will host its second-quarter earnings conference call on July 15, which is routine corporate communication rather than a price-moving event on its own. Article Title
• Negative Sentiment: Broader commentary highlighted that J&J still faces exposure from patent-loss pressure on older products, even though oncology growth and MedTech demand are helping offset it. This remains an overhang on the stock’s longer-term earnings mix. Article Title

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $225.16 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The stock's fifty day moving average price is $233.02 and its two-hundred day moving average price is $224.82. Johnson & Johnson has a one year low of $149.04 and a one year high of $251.71. The firm has a market cap of $542.01 billion, a price-to-earnings ratio of 26.03, a P/E/G ratio of 2.21 and a beta of 0.27.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.02. The firm had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The company's revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities analysts forecast that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be given a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Tuesday, May 26th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.30. Johnson & Johnson's dividend payout ratio is currently 61.97%.

Analyst Ratings Changes

A number of research analysts have issued reports on JNJ shares. Stifel Nicolaus lifted their price objective on Johnson & Johnson from $220.00 to $250.00 and gave the company a "hold" rating in a report on Wednesday, April 15th. Guggenheim lifted their price target on Johnson & Johnson from $244.00 to $266.00 and gave the company a "buy" rating in a report on Monday, April 20th. TD Cowen assumed coverage on Johnson & Johnson in a research report on Wednesday, April 8th. They issued a "buy" rating and a $250.00 price objective for the company. Wells Fargo & Company raised their target price on Johnson & Johnson from $240.00 to $263.00 and gave the stock an "overweight" rating in a report on Wednesday, April 15th. Finally, Rothschild & Co Redburn lifted their price objective on Johnson & Johnson from $180.00 to $210.00 and gave the company a "neutral" rating in a report on Thursday, February 19th. Twenty investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus price target of $253.04.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.